All.Can International

Tweet this page
Registration as it was on 13 Feb 2024
How to read and use this data card.
Download this datacard


Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

Lobbying Costs

None declared

Financial year: Jan 2023 - Dec 2023

Lobbyists (Full time equivalent)

0.75 Fte (2)

Lobbyists with EP accreditation


High-level Commission meetings


Lobbying Costs over the years

  • Info

    All.Can International

    EU Transparency Register

    025568638034-92 First registered on 05 May 2020

    Goals / Remit

    All.Can International is a global, multi-stakeholder initiative to inform and generate political and public engagement on the need to improve the efficiency of cancer care, by focusing on what really matters to patients and the society. All.Can seeks to make sure resources are directed towards achieving better health outcomes while contributing to health systems’ overall sustainability.

    All.Can's objectives are:
    1. Advancing thought leadership in cancer care efficiency
    2. Driving cancer care policy & multi-stakeholder dialogue
    3. Improving cancer care control, systems & pathways globally & locally

    Main EU files targeted

    • Europe’s Beating Cancer Plan
    • Horizon Europe Cancer Mission
    • European Health Data Space
    • EU4Health
    • SmartCard
    • 4P-CAN


    Head Office
    Rue du Luxembourg 22-24
    Brussels 1000
    EU Office
    Rue du Luxembourg 22-24
    Brussels 1000


  • People

    Total lobbyists declared


    Employment timeLobbyists

    Lobbyists (Full time equivalent)


    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 23 Jul 2024

    Name Start date End Date
    Mr Eduardo PISANI 06 Dec 2022 06 Dec 2023
    Mr Eduardo PISANI 24 Nov 2021 24 Nov 2022

    Complementary Information

    All.Can does not have any direct employees. The information above relates to freelance and consultant staff.

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories


    Non-governmental organisations, platforms and networks and similar

  • Networking


    Union for International Cancer Control (UICC);
    European Alliance for Value in Health (EAVH)

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Does not represent commercial interests

    Closed financial year

    Jan 2023 - Dec 2023

    Lobbying costs for closed financial year

    Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

    Total organisational budget in closed year


    Major funding types in closed year

    Grants, EU funding, Member's contribution

    Major contributions in closed year

    Contribution Bristol Myers Squibb (BMS) 140,000€
    Contribution Roche (Hoffmann) 75,000€
    Contribution MSD 75,000€
    Contribution Janssen (J&J) 80,000€
    Contribution Illumina 30,000€
    Contribution Amgen 25,000€
    Contribution Roche additional metrics support (Playbook project) 30,000€
    Contribution Medical Nutrition Industry MNI 20,000€
    Contribution EFPIA grant 75,000€
    Contribution EU project: 4P-Can 3-yr project (40% of 315,937.50 applied to 2024) 31,594€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)


    Groups (European Parliament)


    Communication activities

    In 2019, All.Can published the findings of a patient survey conducted in over 10 countries with almost 4,000 cancer patients and carers, revealing where they identified inefficiencies in their care.
    In 2021, All.Can published a policy report entitled ‘Harnessing data for better cancer care', assessing the essential role of data in cancer care to improve outcomes for all people with cancer, and offering policymakers, care providers, patients and decision-makers a forward-looking recommendations on how to ensure high-quality health data are systematically collected and used to improve outcomes for patients across the entire cancer care pathway.
    In 2022, All.Can published its ‘Building efficiency in cancer care’ policy blueprint, offering a common, broadly applicable framework to support collaborative policy action to improve efficiency in cancer care, for better patient outcomes and more sustainable healthcare systems.
    On 17 June 2022, All.Can published its Efficiency Metrics study, a policy research which proposes a set of internationally applicable and real-world measures generated and collected from daily clinical practice. The report can be used by relevant stakeholders to assess efficiency in cancer care and aims to harmonise and set standards in cancer care efficiency globally.

    Other activities

    None declared

  • Meetings


    None declared

Download this datacard